Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080030/S027

iStent Trabecular Micro-Bypass Stent System

Glaukos Corporation · Decision date Apr 8, 2026

FDA DECISIONP080030/S027

What did the FDA approve?

FDA records P080030/S027 as a supplement to PMA P080030, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 8, 2026.

FDA approval order statement

two new packaging sealers with new sealing parameters used during routine packaging of the iStent Trabecular Micro-Bypass Stent System.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ophthalmic
Decision date
Apr 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P080030/S027
Regulatory pathway
PMA supplement
Product code
OGO
Decision code
APPR
Decision date
Apr 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intraocular pressure lowering implant.

Product code
OGO
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P080030/S027 received

    Application receipt date recorded by FDA.

  2. P080030/S027 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P080030. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code OGO

Product / regulatory recordCompanyPathwayDecision dateSource
Glaukos CorporationPMA supplementOct 1, 2026FDA
Hydrus MicrostentP170034/S018
Alcon Research, LLCPMA supplementJun 4, 2026FDA
Hydrus MicrostentP170034/S017
Alcon Research, LLCPMA supplementApr 23, 2026FDA
Glaukos CorporationPMA approvalJun 21, 2018FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Glaukos Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
26051 Merit Cir., Suite 103, Laguna Hills, CA, 92653

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records